HYPD

Hyperion DeFi Inc

Sep 17 • 11:46AM ET

12.70

+1.15 9.96 %

Healthcare • Biotechnology • USA • NASD

Peers: ALDX OCUL EDIT KALA XERS NCNA PRPH CRVS PRQR OPTN

Index	-	P/E	-	EPS (ttm)	-30.66	Insider Own	83.86%	Shs Outstand	4.85M	Perf Week	19.81%
Market Cap	72.32M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.92M	Perf Month	70.24%
Enterprise Value	73.26M	PEG	-	EPS next Q	-	Inst Own	2.46%	Short Float	116.19%	Perf Quarter	82.21%
Income	-40.11M	P/S	1807.96	EPS this Y	-	Inst Trans	-47.28%	Short Ratio	0.40	Perf Half Y	665.06%
Sales	0.04M	P/B	1.65	EPS next Y	-	ROA	-107.21%	Short Interest	1.07M	Perf YTD	8.73%
Book/sh	7.70	P/C	9.60	EPS next 5Y	-	ROE	-228.74%	52W High	47.33 -73.17%	Perf Year	-70.42%
Cash/sh	1.32	P/FCF	-	EPS past 3/5Y	-15.48% 12.70%	ROIC	-88.46%	52W Low	0.85 1394.12%	Perf 3Y	-93.44%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-84.00% -	Gross Margin	-8650.05%	Volatility	29.76% 17.92%	Perf 5Y	-95.46%
Dividend TTM	-	EV/Sales	1831.46	EPS Y/Y TTM	52.13%	Oper. Margin	-60666.85%	ATR (14)	1.78	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.91	Sales Y/Y TTM	41.50%	Profit Margin	-90270.16%	RSI (14)	64.50	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.91	EPS Q/Q	85.00%	SMA20	54.99%	Beta	2.56	Target Price	2.00
Payout	-	Debt/Eq	0.23	Sales Q/Q	-100.00%	SMA50	44.29%	Rel Volume	0.60	Prev Close	11.55
Employees	14	LT Debt/Eq	0.21	Earnings	Aug 13 AMC	SMA200	148.41%	Avg Volume	2.65M	Price	12.70
IPO	Jan 25, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	604,899	Change	9.96%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-24	Downgrade	H.C. Wainwright	Buy → Neutral	$12 → $2
Mar-01-21	Initiated	Northland Capital	Outperform	$10
Feb-03-20	Downgrade	Oppenheimer	Outperform → Perform

Sep-16-25 08:00AM	Hyperion DeFi Enters Into First HAUS Agreement With Proprietary Trading Firm Credo (GlobeNewswire)
Sep-12-25 09:00AM	Corporate Treasury Revolution Accelerates as $113 Billion Bitcoin Holdings Spark 150% Stock Surges (PR Newswire) +24.94%
Sep-09-25 08:00AM	Hyperion DeFi Strengthens Leadership Team With Key Appointments to Accelerate DeFi Strategy (GlobeNewswire) +35.03%
Sep-05-25 10:55AM	Corporate Crypto Treasury Surge Accelerates as Bitcoin Hits Fresh Institutional Milestone (PR Newswire)
Aug-14-25 03:14AM	Hyperion DeFi Inc (HYPD) Q2 2025 Earnings Call Highlights: Strategic Innovations and Financial ... (GuruFocus.com)
04:01PM	Loading…
Aug-13-25 04:01PM	Hyperion DeFi Provides Corporate Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-12-25 09:40AM	Hyperion DeFi Inc (HYPD) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com) -7.66%
Aug-08-25 04:05PM	Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025 (GlobeNewswire) +35.64%
Jul-28-25 08:00AM	Hyperion DeFi Purchases Additional $5 Million in HYPE for Kinetiq iHYPE Strategy (GlobeNewswire) +23.38%
Jul-17-25 08:00AM	Hyperion DeFi to Host Corporate Update Event to Discuss Strategic Evolution from Eyenovia and the Future of On-Chain Finance on July 29, 2025 (GlobeNewswire)
Jul-14-25 04:05PM	Hyperion DeFi Adds $5 Million in HYPE to its Treasury Holdings (GlobeNewswire) -9.07% +7.11%
Jul-02-25 08:00AM	Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc. (GlobeNewswire) +49.81%
Jun-30-25 08:00AM	Eyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain Engagement (GlobeNewswire)
Jun-25-25 08:30AM	Eyenovia Announces Co-Branded Validator with Kinetiq (GlobeNewswire) +5.88%
Jun-23-25 08:30AM	Eyenovia Announces Closing of $50 Million Private Placement, Successful Accumulation of More Than One Million HYPE Tokens, and Update on its Optejet Development Program (GlobeNewswire) +30.17%
02:04PM	Loading…
Jun-18-25 02:04PM	Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings (PR Newswire) -30.70%
08:32AM	Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group (GlobeNewswire)
Jun-17-25 02:55PM	Eyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy (GlobeNewswire) +134.68%
May-19-25 05:30PM	Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results (GlobeNewswire) +47.79%
Apr-10-25 07:00AM	Eyenovia Provides Development Update on Optejet User Filled Device (UFD) (GlobeNewswire)
Mar-20-25 03:11PM	Eyenovia Shares Drop 14% Amid Betaliq Merger Talks (GuruFocus.com) -13.77%
10:24AM	Eyenovia falls on plans to seek reverse merger (SeekingAlpha)
07:00AM	Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq (GlobeNewswire)
Feb-26-25 07:00AM	Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements (GlobeNewswire) +16.56%
Feb-24-25 07:00AM	Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives (GlobeNewswire) -5.36%
Feb-05-25 07:00AM	Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device (GlobeNewswire) -12.82%
Jan-28-25 04:05PM	Eyenovia Announces 1-for-80 Reverse Stock Split (GlobeNewswire) -34.74%
Jan-15-25 07:00AM	Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote FOR Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders (GlobeNewswire) -23.37%
Jan-06-25 07:00AM	Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives (GlobeNewswire) +9.17%
Dec-06-24 08:00AM	Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering (GlobeNewswire) -9.49%
08:00AM	Loading…
Nov-25-24 08:00AM	Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering (GlobeNewswire) -17.38%
Nov-23-24 07:05AM	Eyenovia taking additional actions to reduce personnel-related costs by over 70% (TipRanks)
Nov-22-24 07:00AM	Eyenovia Provides Update on Restructuring Efforts (GlobeNewswire)
Nov-19-24 06:15AM	Eyenovia downgraded to Neutral from Buy at H.C. Wainwright (TipRanks) +7.39%
Nov-18-24 07:38AM	Eyenovia stock plummets following Phase III myopia trial failure (Clinical Trials Arena) +8.93%
Nov-15-24 01:15PM	Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline (Benzinga) -70.04%
07:00AM	Eyenovia Provides Update on Phase 3 CHAPERONE Study (GlobeNewswire)
Nov-13-24 02:17AM	Eyenovia Inc (EYEN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com) -19.35%
Nov-12-24 05:45PM	Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +8.85%
04:05PM	Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-24 07:00AM	Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th (GlobeNewswire)
Oct-23-24 07:00AM	Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet (GlobeNewswire)
Oct-16-24 07:00AM	Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo (GlobeNewswire) +22.17%
Oct-14-24 09:55AM	Here's Why Eyenovia (EYEN) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Oct-09-24 06:13PM	Eyenovia Inc (EYEN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Oct-01-24 07:00AM	Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device (GlobeNewswire)
Sep-27-24 08:30AM	Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering (GlobeNewswire) +6.93%
Sep-26-24 07:00AM	Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery (GlobeNewswire)
Sep-09-24 06:53AM	Formosa Pharma ships APP13007 ophthalmic drug to US (Pharmaceutical Technology) +14.35%
03:00AM	Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization (PR Newswire)
Sep-05-24 07:00AM	Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S. (GlobeNewswire)
Sep-03-24 07:00AM	Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer (GlobeNewswire)
Aug-23-24 11:42AM	Eyenovia Announces Closing of Public Offering (GlobeNewswire) +6.53%
Aug-21-24 09:29AM	Eyenovia Announces Pricing of $5.14 Million Public Offering (GlobeNewswire) -31.64%
Aug-20-24 05:09PM	Eyenovia, Inc. Announces Proposed Public Offering (GlobeNewswire) -17.03%
Aug-15-24 12:00PM	Eyenovia (EYEN) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-13-24 07:00AM	Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) -9.08%
Aug-12-24 05:30PM	Eyenovia, Inc. (EYEN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-24 07:00AM	Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th (GlobeNewswire) -6.16%
Aug-07-24 05:11PM	Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. (GlobeNewswire)
08:00AM	Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States (PR Newswire)
Jul-30-24 08:00AM	Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease (GlobeNewswire)
Jul-23-24 07:00AM	Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease (GlobeNewswire) +14.17%
Jul-01-24 06:50AM	NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities (Business Wire) +14.27%
Jun-28-24 08:00AM	Eyenovia Announces Pricing of $5M Registered Direct Offering (GlobeNewswire) -14.16%
May-23-24 06:00AM	Peek Behind the Curtain: 7 Penny Stocks With Heavy Insider Buying (InvestorPlace) -7.49%
May-20-24 12:00PM	All You Need to Know About Eyenovia (EYEN) Rating Upgrade to Buy (Zacks)
May-16-24 03:07AM	Eyenovia Inc (EYEN) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ... (GuruFocus.com) -22.56%
May-15-24 08:55PM	EYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) +28.28%
04:01PM	Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol (GlobeNewswire)
May-14-24 07:00AM	Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th (GlobeNewswire)
May-10-24 06:31AM	Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension (Pharmaceutical Technology)
Apr-25-24 07:00AM	Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension (GlobeNewswire) +21.90%
Apr-09-24 09:29AM	Eyenovia (EYEN) Down 18% on Disappointing Corporate Update (Zacks) -15.73%
Apr-08-24 07:00AM	Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities (GlobeNewswire) -17.99%
Apr-03-24 07:00AM	Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings (GlobeNewswire) -6.63%
Mar-27-24 11:28AM	NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:57AM	Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-19-24 08:50AM	Eyenovia, Inc. (NASDAQ:EYEN) Q4 2023 Earnings Call Transcript (Insider Monkey) -23.20%
06:41AM	Q4 2023 Eyenovia Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-18-24 08:53PM	EYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:20PM	Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-13-24 07:00AM	NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals (GlobeNewswire)
Mar-11-24 07:00AM	Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th (GlobeNewswire)
Mar-05-24 12:59PM	Beyond Cataract Surgery: Analyst Highlights Broader Market Potential For Eyenovia/Formosa's Steroid For Post-Eye Surgery Pain, Inflammation (Benzinga) -22.81%
08:00AM	Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery (GlobeNewswire)
Mar-04-24 06:21PM	UPDATE 2-US FDA approves Eyenovia's eye drug, Formosa Pharma says (Reuters)
06:06PM	US FDA approves Eyenovia's eye drug, Formosa Pharma says (Reuters)
Feb-13-24 07:00AM	Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility (GlobeNewswire) -5.76%
Jan-26-24 09:22AM	Formosa, fresh from Eyenovia deal, sells Brazilian rights to near-approval eye drug (FierceBiotech.com)
Jan-16-24 07:00AM	Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada (GlobeNewswire) -7.51%
Dec-15-23 08:17AM	7 Promising Penny Stocks With the Potential to Defy Expectations (InvestorPlace)
Nov-14-23 10:38AM	Eyenovia, Inc. (NASDAQ:EYEN) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.04%
Nov-13-23 04:05PM	Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-23 08:00AM	Eyenovia to Report Third Quarter 2023 Results on Monday, November 13 (GlobeNewswire) -8.74%
Nov-02-23 07:00AM	Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production (GlobeNewswire)
Oct-30-23 03:52PM	Billionaire Marc Lasrys Top 10 Stock Picks (Insider Monkey) +6.48%
07:00AM	Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO's 51st Annual Continuing Education (ACE) Program (GlobeNewswire)

Hyperion DeFi, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in Laguna Hills, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MATHER CHARLES E IV	Director	Jul 22 '25	Proposed Sale	12.86	1,362	17,515		Jul 22 11:20 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HYPD

Hyperion DeFi Inc

Upgrade your FINVIZ experience